X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - FINANCIALPOST.COM - A La Une - 14/Feb 00:47

Theratechnologies Resumes Distribution of EGRIFTA SV®

MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announced that it has resumed distribution of EGRIFTA SV® (tesamorelin for injection), following correspondence from the U.S. […]

Articles similaires

Sorry! Image not available at this time

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of Qtorin 3.9% Rapamycin Anhydrous Gel (Qtorin rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

drugs.com - 10/Feb 02:02

WAYNE, Pa., Feb. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company...

Sorry! Image not available at this time

FDA Approves Gomekli (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

drugs.com - 11/Feb 22:02

STAMFORD, Conn., Feb. 11, 2025 -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare...

Sorry! Image not available at this time

CARsgen's first enrolled subject in the THANK─u Plus platform─based allogeneic CAR─T trial achieves sCR at week 4

pharmabiz.com - 11/Feb 19:24

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T─cell therapies for the treatment of hematologic malignancies and solid...

Sorry! Image not available at this time

Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery

news.medical.net - 04:37

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel...

Sorry! Image not available at this time

Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma

drugs.com - 18/Feb 03:02

DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that...

Sorry! Image not available at this time

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

financialpost.com - 10/Feb 12:01

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in...

Sorry! Image not available at this time

Century Announces Filing of Third Quarter Financial Results and Management Discussion and Analysis for Nine Months Ended December 31, 2024

financialpost.com - 13/Feb 13:03

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWS AGENCIES HONG KONG, Feb. 13, 2025 (GLOBE NEWSWIRE) — Century...

Sorry! Image not available at this time

Primaris REIT Announces Distribution for February 2025

reitreport.ca - 12/Feb 03:01

TORONTO--(BUSINESS WIRE)--Primaris Real Estate Investment Trust (“Primaris” or the “Trust”) (TSX: PMZ.UN) announced today that its Board of...

Sorry! Image not available at this time

BridgeBio Pharma announces EU grants marketing authorization to Beyonttra to treat transthyretin amyloidosis in adults with cardiomyopathy

pharmabiz.com - 13/Feb 06:52

BridgeBio Pharma, Inc., a new type of biopharmaceutical company focused on genetic diseases, announced the European Commission has granted marketing...

Sorry! Image not available at this time

ERES Declares February 2025 Monthly Distribution

reitreport.ca - 18/Feb 22:00

TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) — European Residential Real Estate Investment Trust (TSX: ERE.UN, “ERES”) is pleased to announce that...

Les derniers communiqués